Despite the fact that the combined usage of EGFR- and RAS-targeting drugs in clinical practice enhances the effectiveness of cancer treatment [32], MAPK signaling inhibitors cause cell resistance by activating compensatory feedback loops in tumor cells and tumor microenvironment components [33, 34]. This evidence concerns the gene EGFR and neoplasm.